Stichting EuroQol Research Foundation
Stichting EuroQol Research Foundation is recorded as a service provider in 21 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 21 trials · Latest update first
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- Approximately 50% of the first 22 Part 1 participants experienced on-treatment ALT elevations, and protocol management criteria were amended because some elevations were prolonged.
- New enrollment was temporarily halted in December 2022 after significant ALT elevations were observed more frequently in Part 2 participants with screening or baseline HBsAg >10,000 IU/mL.
- Enrollment was not reopened because the sponsor discontinued further investment in its hepatitis B and D discovery and development programs.
- Part 2 open-label treatment was reduced to Week 96 and follow-up to 24 weeks under protocol amendment 5.
- Sustained HBV response was not collected or analyzed because follow-up was shortened and participants continued NA treatment during follow-up.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)
Sponsor Insmed Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Sponsor Insmed Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy - EMN17/54767414MMY3014
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study).
Sponsor Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start (EU)
- Latest update
- Estimated end
Operational learnings available6 trial-level findings · Read insights
- Of 336 screened patients, 102 initially failed screening; 15 were rescreened and 13 subsequently became eligible.
- Protocol Version 5.0 excluded confirmed COVID-19 from the major-infection definition for the primary endpoint and clarified the effect of altered COVID-19 hospital-admission criteria on major-infection reporting.
- Protocol Version 6.0 permitted repeat IgG testing during screening and rescreening for any patient who failed screening.
- Protocol Version 6.0 removed the scheduled additional safety-panel laboratory visit 7–10 days after the first investigational-product infusion.
- Protocol Version 7.0 added sites in Türkiye, Greece, Spain, and the Czech Republic, removed Israel, and increased the planned site count from approximately 50 to 70.
- No global trial interruptions or restarts were reported.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP).
Sponsor Principia Biopharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyClad)
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Sponsor Insmed Inc.
- Start (EU)
- Latest update
- Estimated end
A single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric subjects with relapsed/refractory (r/r) mature B-cell neoplasms who have relapsed after one or more prior therapies, including subjects with primary refractory disease
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adenoassociated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
GSDIa Disease Monitoring Program
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
EORTC 2022-MG: Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study (ATOM Trial)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of Rilzabrutinib (PRN1008), an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia
Sponsor Principia Biopharma Inc.
- Start (EU)
- Latest update
- Estimated end
C5691003_A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) ECHELON-3
Sponsor Seagen Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)
Sponsor Medac Gesellschaft fuer klinische Spezialprapaerate mbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Sponsor GB002 Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 / Phase 3, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Adaptive Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Stichting EuroQol Research Foundation?
The 2026-10-09 snapshot links Stichting EuroQol Research Foundation to 21 distinct CTIS trials. Recorded services include Clinical outcome assessments, Electronic data capture, EQ-5d-5L questionnaire license, Patient questionnaires, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Stichting EuroQol Research Foundation?
The most frequently recorded therapeutic areas are Immunology, Cardiology, Haematological Malignancies, Respiratory. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Stichting EuroQol Research Foundation conducted?
The linked trials record locations in 21 countries, including Spain, Italy, France, Germany, Poland. These are trial locations, not confirmed office locations or countries where Stichting EuroQol Research Foundation delivered services.
What can this page tell me about Stichting EuroQol Research Foundation's trial experience?
Browse 21 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Stichting EuroQol Research Foundation. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Stichting EuroQol Research Foundation